abstract |
The present invention relates to novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkyne receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical methods for preparing these compounds and CX3CR1 in animals, particularly humans Disclosed are their use in the treatment or prevention of diseases associated with receptor activity. |